Home Medicine Reference range for C1-esterase inhibitor (C1 INH) in the third trimester of pregnancy
Article
Licensed
Unlicensed Requires Authentication

Reference range for C1-esterase inhibitor (C1 INH) in the third trimester of pregnancy

  • Hiroaki Tanaka ORCID logo EMAIL logo , Kayo Tanaka , Naosuke Enomoto , Sho Takakura , Shoichi Magawa , Shintaro Maki , Masafumi Nii , Kuniaki Toriyabe , Shinji Katsuragi and Tomoaki Ikeda
Published/Copyright: September 4, 2020

Abstract

Objectives

The objectives of this study were to (i) establish the reference range and mean value for normal levels of C1-esterase inhibitor (C1 INH) during pregnancy, and (ii) investigate the association between C1 INH and uterine atony, as measured by blood loss at delivery.

Methods

We prospectively studied 200 healthy pregnant women who were registered. We studied C1 INH levels in 188 women at 34 and 35 gestational weeks of pregnancy. The reference range for C1 INH during the third trimester of pregnancy was calculated using the value of C1 INH that was determined at registration.

Results

The mean value of C1 INH was determined to be 70.3% (95% confidence interval, 68.7–71.9). While the C1 INH levels in four women were determined to be 40% lower than the calculated mean value, amniotic fluid embolism (AFE) did not occur in any of the women studied.

Conclusions

This study successfully demonstrated that a reference value for C1 INH activity can be established using the methods described herein. Further research is needed to determine whether C1 INH is involved in obstetric coagulopathy syndrome such as amniotic fluid embolism.


Corresponding author: Hiroaki Tanaka, MD, PhD, Department of Obstetrics and Gynecology, Mie University Faculty Medicine, 2-174 Edobashi, Tsu, Mie, Japan, Phone: +81 59 232 1111, Fax: +81 59 231 5202, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: This study was approved by the Institutional Review Board of Mie University Hospital on March 17th, 2017 (approval no. 3081).

References

1. Conde-Agudelo, A, Romero, R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol 2009;201:e1–e13. 445. https://doi.org/10.1016/j.ajog.2009.04.052.Search in Google Scholar PubMed PubMed Central

2. Clark, SL, Hankins, GD, Dudley, DA, Dildy, GA, Porter, TF. Amniotic fluid embolism. Analysis of the national registry. Am J Obstet Gynecol 1995;172:1158–67. 10.1016/0002-9378(95)91474-9.10.1016/0002-9378(95)91474-9Search in Google Scholar PubMed

3. Tuffnell, DJ. United Kingdom amniotic fluid embolism register. BJOG 2005;112:1625–9. https://doi.org/10.1111/j.1471-0528.2005.00770.x.Search in Google Scholar PubMed

4. Randoff, OD, Lepow, IH. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 1957;106:327–43. https://doi.org/10.1084/jem.106.2.327.Search in Google Scholar PubMed PubMed Central

5. Donaldson, VH, Evans, RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1-esterase. Am J Med 1963;35:37–44. https://doi.org/10.1016/0002-9343(63)90162-1.Search in Google Scholar PubMed

6. Osler, W. Landmark publication from the American Journal of the Medical Sciences: hereditary angio-neurotic oedema. 1888. Am J Med Sci 2010;339:175–8. https://doi.org/10.1097/MAJ.0b013e3181b2803f.Search in Google Scholar PubMed

7. Horiuchi, T, Ohi, H, Ohsawa, I, Fujita, T, Matsushita, M, Okada, N, et al. Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research – secondary publication. Allergol Int 2012;61:559–62. https://doi.org/10.2332/allergolint.12-rai-0471.Search in Google Scholar

8. Farkas, H, Martinez-Saguer, I, Bork, K, Bowen, T, Craig, T, Frank, M, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017;72:300–13. https://doi.org/10.1111/all.13001.Search in Google Scholar PubMed PubMed Central

9. Tamura, N, Kimura, S, Farhana, M, Uchida, T, Suzuki, K, Sugihara, K, et al. C1 esterase inhibitor activity in amniotic fluid embolism. Crit Care Med 2014;42:1392–6. https://doi.org/10.1097/ccm.0000000000000217.Search in Google Scholar

10. Tamura, N, Farhana, M, Oda, T, Itoh, H, Kanayama, N. Amniotic fluid embolism: pathophysiology from the perspective of pathology. J Obstet Gynaecol Res 2017;43:627–32. https://doi.org/10.1111/jog.13284.Search in Google Scholar PubMed

11. Riedl, MA. Hereditary angioedema with normal C1-INH (HAE type III). J Allergy Clin Immunol Pract 2013;1:427–32. https://doi.org/10.1016/j.jaip.2013.06.004.Search in Google Scholar PubMed

12. Davis, AE3rd. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988;6:595–628. https://doi.org/10.1146/annurev.iy.06.040188.003115.Search in Google Scholar PubMed

13. Kaplan, AP. Bradykinin and the pathogenesis of hereditary angioedema. World Allergy Organ J 2011;4:73–5. https://doi.org/10.1097/wox.0b013e318216b7b2.Search in Google Scholar

Received: 2020-03-06
Accepted: 2020-08-21
Published Online: 2020-09-04
Published in Print: 2021-02-23

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Review
  3. Methods of detection and prevention of preterm labour and the PAMG-1 detection test: a review
  4. Corner of Academy
  5. Long term alterations of growth after antenatal steroids in preterm twin pregnancies
  6. Original Articles – Obstetrics
  7. SARS-CoV-2 in pregnancy: maternal and perinatal outcome data of 34 pregnant women hospitalised between May and October 2020
  8. Comparison of hematological parameters and perinatal outcomes between COVID-19 pregnancies and healthy pregnancy cohort
  9. The effect of mask use on maternal oxygen saturation in term pregnancies during the COVID-19 process
  10. Risk factors for pregnancy-associated venous thromboembolism in Singapore
  11. Does the length of second stage of labour or second stage caesarean section in nulliparous women increase the risk of preterm birth in subsequent pregnancies?
  12. Reference range for C1-esterase inhibitor (C1 INH) in the third trimester of pregnancy
  13. Termination of pregnancy following a Down Syndrome diagnosis: decision-making process and influential factors in a Muslim but secular country, Turkey
  14. High dose vs. low dose oxytocin for labor augmentation: a systematic review and meta-analysis of randomized controlled trials
  15. Extremely high levels of alkaline phosphatase and pregnancy outcome: case series and review of the literature
  16. Cervical elastography strain ratio and strain pattern for the prediction of a successful induction of labour
  17. Original Articles – Fetus
  18. CD34 immunostain increases sensitivity of the diagnosis of fetal vascular malperfusion in placentas from ex-utero intrapartum treatment
  19. The ability of various cerebroplacental ratio thresholds to predict adverse neonatal outcomes in term fetuses exhibiting late-onset fetal growth restriction
  20. Obstetric and pediatric growth charts for the detection of late-onset fetal growth restriction and neonatal adverse outcomes
  21. Original Articles – Neonates
  22. Bacterial stability with freezer storage of human milk
  23. Protein and genetic expression of CDKN1C and IGF2 and clinical features related to human umbilical cord length
  24. Short Communication
  25. A considerable asymptomatic proportion and thromboembolism risk of pregnant women with COVID-19 infection in Wuhan, China
Downloaded on 1.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jpm-2020-0099/html
Scroll to top button